Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Status:
Terminated
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
This prospective multicenter non-randomized controlled study evaluates the efficacy and
safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with
microvascular invasion after radical resection compared to conventional therapies.